Solara Active Pharma Sciences Ltd Q2FY26 – From Ibuprofen Hangover to API Resurrection, a ₹3,140 mn Reality Check
1. At a Glance
Welcome to Solara Active Pharma Sciences Ltd (NSE: SOLARA), where API doesn’t just stand for Active Pharmaceutical Ingredient — it’s also Always Problematic Instincts. The company, once the crown jewel of Strides Shasun’s demerged API unit, is crawling its way out of a ₹567 crore loss hangover (FY24), now attempting a comeback with the intensity of a Bollywood sequel nobody asked for — but everyone’s watching anyway.
At ₹617 a share (Nov 4 close), Solara commands a market cap of ₹2,751 crore, down 22.7% over the past year but up 22.6% in the last six months. It trades at a comically inflated P/E of ~750, which is Wall Street’s way of saying “we believe in miracles.” Its ROE sits at -0.11%, and debt at ₹646 crore (D/E 0.51). Q2FY26 revenue was ₹3,140 million (-10% YoY), EBITDA ₹352 million, and a PAT loss of ₹101 million — better than a ₹567 crore bloodbath last year, but still a patient in the ICU.
Operating margin stands at 15.9%, and interest coverage barely limps at 1.04x — a financial cardio workout for analysts. The promoters hold 42%, with 35.3% pledged, which in smallcap language translates to “Haan bhai, thoda tension hai.”
But wait — the company just raised ₹450 crore via a rights issue, repaid ₹118 crore of debt, and is now spinning off its CRAMS and Polymer businesses. The stage is set for a second act. Whether it’s Pathaan or Tashan, we’ll find out soon.
2. Introduction
Once upon a time in the Indian API jungle, Solara was the ambitious spin-off that promised purity of purpose: one company, one product category, one obsession — APIs. Born from the demerger of Strides Shasun and joined by Sequent’s human API business, Solara strutted onto Dalal Street with a swagger. But like many “pure plays,” the script didn’t stay pure for long.
The company’s early glory days saw it clock over ₹1,600 crore in sales and margins near 24%. Then came the fall — ibuprofen oversupply, inventory write-offs, receivable chaos, and a ₹567 crore loss that made analysts whisper “ouch” in muted tones on concalls. The FY24 results were an accounting horror show: negative operating margins, and more impairments than a soap opera twist.
Fast forward to FY25–26. The CEO’s message reads like a redemption arc: shutting down unprofitable units, streamlining plants, and raising ₹450 crore to strengthen the balance sheet. They’ve gone from “mass-producing painkillers” to “managing shareholder pain.”
In a quarter that saw Mangalore shutdowns, ESOP grants, a new Chief Human Resources Officer, and “no deviation in rights issue fund utilization,” Solara seems to be finally walking the talk — though barefoot on a bed of nails.
And investors? They’re torn between calling it a turnaround story or a science experiment gone right for once.
3. Business Model – WTF Do They Even Do?
Let’s break it down. Solara is a pure-play Active Pharmaceutical Ingredient (API) manufacturer — the “raw materials” behind medicines. Think of them as the spice merchants of pharma — supplying the masala that makes pills effective.
They’ve got 60+ commercial APIs shipped to over 73 countries, across therapeutic areas like anthelmintics (dewormers), antimalarials, and anti-infectives. Their top 10 molecules contribute a massive 84% of total revenue — because diversification is for the weak, apparently.
Their manufacturing spread includes six facilities — each globally compliant, USFDA and EU GMP approved. Translation: “Our plants can legally sell in rich countries.”
Their R&D center in Chennai houses 140+ scientists and has filed 95 DMFs in the US — that’s the passport of every API to enter the regulated markets. In FY24, R&D spend was 4.3% of sales — not bad, though down from 5% in FY22.
And just as things stabilize, Solara announced it will demerge its CRAMS and Polymer businesses. These will take the Vizag facility (and ₹200 crore of debt) to form a ₹120 crore revenue entity — a corporate detox maneuver that makes sense if you squint hard enough.
But will this split improve margins, or is it just moving furniture around on a sinking ship? That’s the million-rupee question.
4. Financials Overview
Metric
Latest Qtr (Q2FY26)
YoY Qtr (Q2FY25)
Prev Qtr (Q1FY26)
YoY %
QoQ %
Revenue
₹3,140 mn
₹3,470 mn
₹3,190 mn
-9.6%
-1.6%
EBITDA
₹352 mn
₹610 mn
₹570 mn
-42.3%
-38.2%
PAT
-₹101 mn
₹80 mn
₹110 mn
-226%
-192%
EPS (₹)
-2.79
2.23
2.91
-225%
-196%
Annualised EPS = -₹2.79 × 4 = -₹11.16 → P/E not meaningful (unless you enjoy math abuse).
Commentary: Revenue dipped slightly as the Mangalore shutdown dragged performance. EBITDA margin of ~11% (vs 18% YoY) shows cost pressures aren’t fully tamed. PAT swung negative again — clearly, profit stability is still “under formulation.”
If there’s one thing Solara’s consistent at, it’s inconsistency.
5. Valuation Discussion – Fair Value Range Only
Let’s play valuation Sudoku.
(a) P/E Method: Annualised EPS = ₹1.02 (FY25 full year). Industry median P/E =
